A Randomized Double Blind Placebo Controlled Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy
Recruiting
99 years or below
All
Phase
3
1 Location
Brief description of study
20.0
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
Updated on
25 May 2021.
Study ID: 842832